Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1979 1
1983 1
1984 1
1985 1
1987 1
1988 2
1989 2
1990 3
1991 1
1992 3
1993 2
1994 4
1995 2
1996 1
1997 4
1998 4
1999 6
2000 2
2001 4
2003 2
2004 1
2005 4
2006 6
2007 16
2008 11
2009 10
2010 18
2011 15
2012 12
2013 23
2014 23
2015 23
2016 39
2017 29
2018 34
2019 33
2020 29
2021 24
2022 14
2023 16
2024 9

Text availability

Article attribute

Article type

Publication date

Search Results

362 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Growth hormone-producing pituitary gland adenoma"
Page 1
Diagnosis and Treatment of Acromegaly: An Update.
Ershadinia N, Tritos NA. Ershadinia N, et al. Mayo Clin Proc. 2022 Feb;97(2):333-346. doi: 10.1016/j.mayocp.2021.11.007. Mayo Clin Proc. 2022. PMID: 35120696 Review.
Acromegaly is typically caused by a growth hormone-secreting pituitary adenoma, driving excess secretion of insulin-like growth factor 1. ...Early diagnosis and adequate treatment are essential to mitigate excess mortality associated with …
Acromegaly is typically caused by a growth hormone-secreting pituitary adenoma, driving excess secretion …
Molecular targets in acromegaly.
Labadzhyan A, Melmed S. Labadzhyan A, et al. Front Endocrinol (Lausanne). 2022 Dec 5;13:1068061. doi: 10.3389/fendo.2022.1068061. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 36545335 Free PMC article. Review.
Molecular therapeutic targets in growth hormone (GH)-secreting adenomas range from well-characterized surface receptors that recognize approved drugs, to surface and intracellular markers that are potential candidates for new drug development. ...The degree of contr …
Molecular therapeutic targets in growth hormone (GH)-secreting adenomas range from well-characterized surface receptors that r …
Acromegaly.
Chanson P, Salenave S, Kamenicky P. Chanson P, et al. Handb Clin Neurol. 2014;124:197-219. doi: 10.1016/B978-0-444-59602-4.00014-9. Handb Clin Neurol. 2014. PMID: 25248589 Review.
Acromegaly is due to excessive production of growth hormone (GH), generally by a pituitary GH-secreting adenoma. ...The rheumatologic, cardiovascular, respiratory, and metabolic consequences of acromegaly determine the prognosis. The diagnosis i …
Acromegaly is due to excessive production of growth hormone (GH), generally by a pituitary GH-secreting adenoma. …
Modern approach to resistant acromegaly.
Giustina A, di Filippo L, Uygur MM, Frara S. Giustina A, et al. Endocrine. 2023 May;80(2):303-307. doi: 10.1007/s12020-023-03317-7. Epub 2023 Feb 15. Endocrine. 2023. PMID: 36790521
BACKGROUND: Targets of acromegaly treatment are normalization of biochemical values, removal/reduction/stabilization of the pituitary mass, control of clinical activity and mortality with a multimodal/multidisciplinary approach. Despite significant technological and pharma …
BACKGROUND: Targets of acromegaly treatment are normalization of biochemical values, removal/reduction/stabilization of the pituitary …
Multidisciplinary management of difficult/aggressive growth-hormone pituitary neuro-endocrine tumors.
Bianchi A, Chiloiro S, Giampietro A, Gaudino S, Calandrelli R, Mazzarella C, Caldarella C, Rigante M, Gessi M, Lauretti L, De Marinis L, Olivi A, Pontecorvi A, Doglietto F. Bianchi A, et al. Front Endocrinol (Lausanne). 2023 May 3;14:1123267. doi: 10.3389/fendo.2023.1123267. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 37206441 Free PMC article. Review.
Growth Hormone-secreting adenomas exhibits variable biological behavior and heterogeneous natural history, ranging from small adenomas and mild disease, to invasive and aggressive neoplasms with more severe clinical picture. ...To date, no clinical, laborator …
Growth Hormone-secreting adenomas exhibits variable biological behavior and heterogeneous natural history, ranging from …
Pituitary tumours: acromegaly.
Chanson P, Salenave S, Kamenicky P, Cazabat L, Young J. Chanson P, et al. Best Pract Res Clin Endocrinol Metab. 2009 Oct;23(5):555-74. doi: 10.1016/j.beem.2009.05.010. Best Pract Res Clin Endocrinol Metab. 2009. PMID: 19945023 Review.
Excessive production of the growth hormone (GH) is responsible for acromegaly. It is related to a pituitary GH-secreting adenoma in most cases. ...The rheumatologic, cardiovascular, respiratory and metabolic consequences determine its prognosis. …
Excessive production of the growth hormone (GH) is responsible for acromegaly. It is related to a pituitary GH-secretin …
Predictive Factors of Somatostatin Receptor Ligand Response in Acromegaly-A Prospective Study.
Ilie MD, Tabarin A, Vasiljevic A, Bonneville JF, Moreau-Grangé L, Schillo F, Delemer B, Barlier A, Figarella-Branger D, Bisot-Locard S, Santos A, Chanson P, Raverot G. Ilie MD, et al. J Clin Endocrinol Metab. 2022 Nov 23;107(11):2982-2991. doi: 10.1210/clinem/dgac512. J Clin Endocrinol Metab. 2022. PMID: 36136828
Finally, SST5 IRS was higher in preoperative hyperintense compared with preoperative hypointense adenomas (P = 0.04), and most sparsely granulated and most hyperintense adenomas expressed high SST5 levels. CONCLUSION: We prospectively confirm that SST2A and adenoma granula …
Finally, SST5 IRS was higher in preoperative hyperintense compared with preoperative hypointense adenomas (P = 0.04), and most sparsely gran …
Pituitary Medicine From Discovery to Patient-Focused Outcomes.
Melmed S. Melmed S. J Clin Endocrinol Metab. 2016 Mar;101(3):769-77. doi: 10.1210/jc.2015-3653. Epub 2016 Feb 23. J Clin Endocrinol Metab. 2016. PMID: 26908107 Free PMC article. Review.
CONTEXT: This perspective traces a pipeline of discovery in pituitary medicine over the past 75 years. OBJECTIVE: To place in context past advances and predict future changes in understanding pituitary pathophysiology and clinical care. ...Challenges facing t …
CONTEXT: This perspective traces a pipeline of discovery in pituitary medicine over the past 75 years. OBJECTIVE: To place in context …
Bone and Joint Disorders in Acromegaly.
Claessen KM, Mazziotti G, Biermasz NR, Giustina A. Claessen KM, et al. Neuroendocrinology. 2016;103(1):86-95. doi: 10.1159/000375450. Epub 2015 Jan 29. Neuroendocrinology. 2016. PMID: 25633971 Free article. Review.
Acromegaly is a chronic, progressive disease caused by a growth hormone (GH)-producing pituitary adenoma, resulting in elevated GH and insulin-like growth factor 1 concentrations. ...In this overview article, we summarize the pathophysiol …
Acromegaly is a chronic, progressive disease caused by a growth hormone (GH)-producing pituitary adenoma, …
A current perspective of pituitary adenoma MRI characteristics: a review.
Gruppetta M. Gruppetta M. Expert Rev Endocrinol Metab. 2022 Nov;17(6):499-511. doi: 10.1080/17446651.2022.2144230. Epub 2022 Nov 13. Expert Rev Endocrinol Metab. 2022. PMID: 36373167 Review.
INTRODUCTION: MR imaging is an essential and fundamental tool in the diagnosis, management, and follow-up of patients with pituitary adenomas (PAs). Recent advances have continued to enhance the usefulness of this imaging modality. ...Further development, refining and vali …
INTRODUCTION: MR imaging is an essential and fundamental tool in the diagnosis, management, and follow-up of patients with pituitary …
362 results